Stock Events

XOMA Royalty 

$26.64
59
+$0+0% Monday 16:39

Statistics

Day High
26.64
Day Low
26.64
52W High
26.64
52W Low
13.96
Volume
1
Avg. Volume
90
Mkt Cap
-
P/E Ratio
295.73
Dividend Yield
-
Dividend
-

Earnings

9MayConfirmed
Q2 2022
Q3 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
-1.87
-1.3
-0.73
-0.16
Expected EPS
-0.81
Actual EPS
-0.86

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 0M26.LSE. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Regeneron Pharmaceuticals
REGN
Mkt Cap118.74B
Regeneron Pharmaceuticals competes in the biotechnology industry focusing on developing and commercializing medicines for serious medical conditions, similar to XOMA's focus on antibody-based therapeutics.
AMGEN
AMGN
Mkt Cap177.47B
Amgen is a biopharmaceutical company that discovers, develops, manufactures, and delivers innovative human therapeutics, competing directly with XOMA in the biotech sector.
Biogen
BIIB
Mkt Cap33.5B
Biogen competes with XOMA in the biotechnology field, focusing on developing therapies for neurological and neurodegenerative diseases.
Gilead Sciences
GILD
Mkt Cap87.16B
Gilead Sciences is a biopharmaceutical company that researches, develops, and commercializes drugs in areas similar to XOMA, making them direct competitors.
Vertex Pharmaceuticals
VRTX
Mkt Cap126.12B
Vertex Pharmaceuticals is involved in creating new possibilities in medicine to cure diseases and improve people's lives, competing with XOMA in the biotech innovation space.
Alnylam Pharmaceuticals
ALNY
Mkt Cap32.95B
Alnylam Pharmaceuticals is a leader in RNAi therapeutics, competing with XOMA in the development of novel therapeutics.
Incyte
INCY
Mkt Cap14.29B
Incyte Corporation focuses on the discovery, development, and commercialization of proprietary therapeutics, making it a competitor in the biopharmaceutical space alongside XOMA.
Nektar Therapeutics
NKTR
Mkt Cap261.31M
Nektar Therapeutics is involved in developing new treatment options in various therapeutic areas, competing with XOMA in the innovation of biologic drugs.
Biomarin Pharmaceutical
BMRN
Mkt Cap16.14B
BioMarin Pharmaceutical focuses on developing and commercializing innovative biopharmaceuticals for rare diseases, competing with XOMA in targeting niche markets with specialized treatments.

About

XOMA Corporation, a biotechnology royalty aggregator, engages in helping biotech companies for improving human health. The company acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. It acquires the future economics, the seller receives non-dilutive, non-recourse funding they can use to advance internal drug candidate or for general corporate purposes. The company has a portfolio with approximately 70 assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.
Show more...
CEO
Mr. James R. Neal
Employees
12
Country
US
ISIN
US98419J2069
WKN
000A2ATUH

Listings